Electrical remodelling post cardiac resynchronization therapy in patients with ischemic and non-ischemic heart failure by Ajaero, Chukwudiebube N et al.
Archived at the Flinders Academic Commons: 
http://dspace.flinders.edu.au/dspace/ 
‘This is the peer reviewed version of the following article: 
Ajaero, C. N., Ganesan, A., Horowitz, J. D., & McGavigan, A. 
D. (2019). Electrical remodelling post cardiac 
resynchronization therapy in patients with ischemic and 
non-ischemic heart failure. Journal of Electrocardiology, 53, 
44–51. https://doi.org/10.1016/j.jelectrocard.2018.12.001 
which has been published in final form at 
https://doi.org/10.1016/j.jelectrocard.2018.12.001
Crown Copyright © 2018 Published by Elsevier Inc.
This manuscript version is made available under the CC-BY-
NC-ND 4.0 license:
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Accepted Manuscript
Electrical remodelling post cardiac resynchronization therapy in
patients with ischemic and non-ischemic heart failure
Chukwudiebube N. Ajaero, Anand Ganesan, John D. Horowitz,
Andrew McGavigan
PII: S0022-0736(18)30485-0
DOI: https://doi.org/10.1016/j.jelectrocard.2018.12.001
Reference: YJELC 52767
To appear in: Journal of Electrocardiology
Please cite this article as: Chukwudiebube N. Ajaero, Anand Ganesan, John D. Horowitz,
Andrew McGavigan , Electrical remodelling post cardiac resynchronization therapy in
patients with ischemic and non-ischemic heart failure. Yjelc (2018), https://doi.org/
10.1016/j.jelectrocard.2018.12.001
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may
be discovered which could affect the content, and all legal disclaimers that apply to the
journal pertain.
AC
CE
PT
ED
 M
AN
US
CR
IPT
TITLE PAGE 
 
 
Title: 
Electrical remodelling post cardiac resynchronization therapy in patients with 
ischemic and non-ischemic heart failure.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 2 
 
AUTHORS 
1. Dr Chukwudiebube N Ajaero MBBS, FMCP, FRACP 
Cardiologist and Electrophysiologist, 
a
The Queen Elizabeth Hospital,  28 Woodville 
road,Woodville South, South Australia 5011. 
 
2. A/Prof Anand Ganesan 
Cardiologist and Electrophysiologist, b Southern Adelaide Local Health Network; 
Matthew Flinders Fellow, Flinders University of South Australia 
Flinders Drive, Bedford Park, South Australia 5042 
 
3. Prof John D Horowitz 
Professor of Medicine, The University of Adelaide, South Australia 
Director of Cardiology, 
a
The Queen Elizabeth Hospital/Basil Hetzel Institute,  
28 Woodville Rd, Woodville South, South Australia 5011 
 
4. Prof Andrew McGavigan 
Professor of Cardiovascular Medicine, Flinders University, South Australia 
Director of Electrophysiology and Pacing, 
b
Flinders Medical Centre, Flinders Drive, 
Bedford Park, South Australia 5042 
             
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 3 
 
 
Corresponding Author: 
Prof Andrew McGavigan 
Professor of Cardiovascular Medicine, Flinders University, South Australia 
Director of Electrophysiology and Pacing, Flinders Medical Centre, South Australia 
Tel: +618 8 2045619 
      Fax: +618 8 2045625 
      E: Andrew.McGavigan@sa.gov.au  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IPT
 4 
 
ABSTRACT: 
Background 
The beneficial effects of cardiac resynchronization therapy (CRT) in heart failure are largely 
considered to be due to improved mechanical contractility. The contributory role of electrical 
remodelling is less clear. We sought to evaluate the impact of electrical remodelling in these 
patients. 
Methods.  
33 patients with conventional indications for CRT and with ischemic (ICM) (n=17) and non-
ischemic (NICM) (n=16) aetiologies for heart failure were prospectively recruited. Functional 
parameters of peak exercise oxygen consumption (VO2max) and Minnesota quality of life (QOL) 
score, echocardiographic measures of LV functions and parameters of electrical remodelling, e.g. 
intrinsic QRS duration (iQRSD), intracardiac conduction times of LV pacing to RV 
electrocardiogram (LVp-RVegm), were measured at  CRT implant and after 6 months.  
Results 
Only two electrical parameters predicted functional or symptomatic improvement. LVp-RVegm 
reduction significantly correlated with improvement in VO2max (r= -0.42, p= 0.03 while 
reduction in iQRSD significantly correlated with improvement in QOL score (r=0.39, p= 0.04). 
The extent of changes in LVp-RVegm and iQRSD was significantly greater in NICM than in 
ICM patients (p=0.017 and p=0.042 for heterogeneity).  There was also significant differential 
impact on QOL score in the NICM relative to the ICM group (p=0.003) but none with VO2max. 
On multivariate analysis, only non-ischemic aetiology was a significant determinant of reduction 
in iQRSD. 
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Conclusion 
CRT induces potentially beneficial reduction in LVp-RVegm and iQRSD, which are seen 
selectively in NICM rather than ICM patients. The extent of improvement in these markers is 
associated with some functional and symptomatic measures of CRT efficacy. 
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1. Electrical remodelling 
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3. Intracardiac conduction time. 
4. Intrinsic QRS duration 
5. Cardiopulmonary exercise testing 
6. Intracardiac electrocardiogram. 
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INTRODUCTION 
Results from previous landmark studies have clearly shown that cardiac resynchronization 
therapy (CRT) reduces morbidity and mortality in patients with chronic systolic heart failure and 
associated prolonged QRS duration [1, 2]. To date, prolonged QRS duration, especially of left 
bundle branch block morphology, remains the best predictor of response to CRT [3]. Indeed, in 
patients with evidence of mechanical dyssynchrony on echocardiogram but with narrow QRS 
duration, CRT is futile and may be associated with harm[4, 5]. In spite of this, the benefit of CRT 
on improved left ventricular volume and systolic function has been considered to be largely 
mediated by reversal of adverse left ventricular mechanical remodelling[6-8] rather than through 
positive electrical remodelling.   
 
Although there are limited data reporting changes in individual electrical parameters following 
CRT, the majority have focused on relatively simple tools such as intrinsic QRS complex 
duration and morphology and QT dispersion [9-11] and have yielded inconsistent results [9]. The 
effects of CRT on other parameters of electrical remodelling are not well characterized, nor are 
the relationships between electrical remodelling and changes to functional status and mechanical 
function. 
 
Furthermore, it is well recognized that CRT is associated with reduction in the occurrence of 
ventricular arrhythmias, especially in patients who achieve echocardiographic improvement in 
LV function and volumes[10]. Although the mechanism is at present unknown, positive electrical 
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remodelling may play a role due to alterations in intra-cardiac electrical conduction and 
refractoriness. 
 
Finally, whether electrical remodelling plays a role in the observation that patients with non-
ischemic aetiology of heart failure (NICM) have greater improvement in left ventricular 
mechanical remodelling following CRT compared to those with an ischemic basis of heart failure 
(ICM)[11] remains to be fully explored.  There are significant differences between patients with 
NICM and ICM. Functional LBBB rather than fixed block has been noted to be more prevalent in 
patients with NICM than in those with ICM [12], perhaps making patients with NICM  more 
amenable to improvement with CRT in electrical parameters and consequently to improvement in 
mechanical function than those with ICM.  
 
In this study, we prospectively evaluated changes in intra-cardiac electrical parameters following 
CRT, utilizing markers of excitability and local and global electrical conduction in patients with 
both ischemic and non-ischemic aetiologies of heart failure.  
 
OBJECTIVES 
1. To evaluate the effects of CRT on reversal of electrical remodelling.  
2. To test the null hypothesis that extent of reversal in electrical remodelling is independent 
of a history of ischemic heart disease. 
3. To test the hypothesis that extent of electrical remodelling predicts functional and/or 
symptomatic improvement post CRT. 
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METHODS 
Patient selection: 
33 patients with either ICM (n=17), (patients with documented prior myocardial infarction based 
on previous history, echocardiographic regional wall motion abnormality consistent with single 
or multi-vessel arterial territory (ies), and or abnormal coronary angiogram) or NICM (n=16) 
(patients with no prior myocardial infarction and whose coronary angiogram have shown no 
significant coronary artery disease) and conventional indications for CRT[13] were recruited 
from three hospital sites and prospectively evaluated at baseline and 6 months after insertion of a 
CRT device. Baseline functional parameters of VO2max and quality of life assessment (utilizing 
the Minnesota Living with Heart Failure Questionnaire) were performed two weeks or less prior 
to the implantation of CRT and baseline electrical parameters were performed immediately after 
implantation of CRT. All parameters were examined for the total cohort and then for the pre-
specified groups of ICM and NICM patients.. 
 
Functional status assessment: 
 
a. Cardio-pulmonary exercise testing: 
Cardio-pulmonary exercise testing (CPET) was performed according to established 
guidelines[14] Briefly, a bicycle ergometer (Model: ergoline/100/200 GmbH, Germany) and 
linked to ExpAir Medisoft S.A Belgique 1.31.02 software was utilized in all cases. Before 
performing each test, the equipment was calibrated both for airflow or volume, including low and 
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high flows (with calculated volumes within +/-3%) using a 3Litre syringe, and also for gases with 
carbon dioxide set at 4% and oxygen at 20%. A semi- automated progressive incremental (ramp) 
protocol, in which the pre-test was set at 0 watts, while the workload started from 10watts and 
increased by 10 watts every minute, was used.  Patients pedalled for a minute on the pre test 
setting of 0 watts before loading commenced. They were encouraged to exercise as long as 
possible, ideally for up to 8 to 12 minutes, and especially aiming to achieve a respiratory 
exchange ratio (RER) of 1 and above, with cycling rate kept at 60-70 revolutions per minute. 
Volitional exhaustion was the usual endpoint although exercise was terminated if a patient 
developed chest pain, acute ischemic changes on the ECG or hypotension. After unloading, the 
patient pedalled for a further 1 minute. Measurements of oxygen consumption (VO2) carbon 
dioxide output (VCO2) ventilator equivalent, (VE) and RER were automatically acquired and 
finally averaged and displayed at 10-second intervals. The highest reading of the three last 
averages at peak exercise was chosen as the VO2 max. 
 
b. Quality of life score 
The self-administered Minnesota Living with Heart Failure Questionnaire [15]assessed quality of 
life score with higher scores indicating lower functional status. 
 
Measures of electrical remodelling: 
Parameters utilized included the intrinsic QRS duration as an overall marker of global 
electrical dyssynchrony, left ventricular pacing to the onset of right ventricular intra-cardiac 
electrocardiogram (LVp-RVegm), right ventricular pacing to the onset of left  
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ventricular intra-cardiac electrocardiogram (RVp-LVegm), calculations of Q-LVegm  and left 
ventricular intra-cardiac electrocardiogram to the end of QRS complex (LVegm-QRSend) as 
markers of inter-ventricular electrical conduction times.   
As regards specific methodology: 
a. Intrinsic QRS duration 
At baseline, intrinsic QRS duration (iQRSD) was measured from the onset of the initial        
deflection of the QRS complex to the end of the terminal deflection using lead II in all 
cases at a sweep speed of 50mm/s. At 6 months, pacing was temporarily turned off for 
120 seconds to enable repeat measurement of intrinsic QRS duration using lead II at a 
sweep speed of 50mm/s. Lead II was utilised in the measurement of intrinsic QRS 
duration in all cases for consistency and also because of the left ventricular apical 
orientation of lead II vector. 
b. Left ventricular pacing to right ventricular intra-cardiac electrocardiogram 
(LVp-RVegm) 
Immediately after insertion of CRT device, the conduction time from the onset of left 
ventricular-only pacing to the onset of the right ventricular intra-cardiac 
electrocardiogram was measured for each patient in milliseconds. For this, pacing was 
temporarily performed from the left ventricular lead only in VVI mode and at 100 
paces per minute for 30 seconds. LVp-RVegm was taken from the last paced 3 beats, 
which ever was longest. 
Measurements were performed at sweep speed of 100mm/s. This measurement was 
repeated 6 months afterwards. No patient had any re-manipulation of the left 
ventricular pacing lead or change in pacing vectors. 
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c   Right ventricular pacing to left ventricular intracardiac electrocardiogram (RVp-
LVegm) 
a. Conduction time from the onset of right ventricular pacing to the onset of left 
ventricular intracardiac electrocardiogram was measured at a sweep speed of 100mm/s 
with the right ventricle paced at 100 paces per minute in VVI mode for 30 seconds. 
RVp-LVegm was taken from the last paced 3 beats, which ever was longest. 
Measurements were performed at sweep speed of 100mm/s. 
Measurement was performed immediately after CRT insertion and was repeated 6 
months afterwards. 
d. Q-LVegm:  
 This measures the interval between the onset of QRS and the onset of   left 
ventricular intra-cardiac electrocardiogram. Lead II was used to measure the onset of 
QRS. 
e. RVegm-LVegm:  
This is the difference between the onset of right ventricular intra-cardiac 
electrocardiogram and the onset of left ventricular intra-cardiac electrocardiogram. 
This denotes the timing difference in the spontaneous depolarization of the right and 
the left ventricles. 
f. Left ventricular intra-cardiac electrocardiogram to the end of QRS                                       
complex (LVegm-QRSend) 
This was calculated as the difference between the intrinsic QRS duration and Q-
LVegm. 
None of the patients had any of the leads repositioned during the study period thereby ensuring 
constant landmarks for the measurements. The LV leads were inserted at the discretion of the 
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implanter aiming at the lateral or posterolateral coronary sinus branch. Leads were not positioned 
in areas where thresholds were high or areas of non-capture. 
 
Echocardiographic measurements: 
All echocardiographic measurements were performed according to the American Society of 
Echocardiography guidelines.[14] A Phillips echocardiogram machine model iE33, 2009, Bothell 
WA, 98041 USA was used for image acquisition, and analyses were performed using Echopac 
Software Only BT 11 Version 113, 2013 General Electric Co. Measurements included left 
ventricular end-diastolic and end-systolic volumes, from which ejection fraction was calculated 
with Simpson’s rule for biplane evaluation. Inter-ventricular mechanical delay (IVMD) was used 
as a measure of mechanical dyssynchrony. IVMD was calculated as the difference between the 
aortic pre- ejection time, measured from the onset of QRS complex and the onset of aortic 
pulsed-wave Doppler velocity in the apical 5-chamberer view and that of the pulmonary pre-
ejection time, measured from the onset of QRS complex and the onset of pulmonary artery pulsed 
wave velocity in the parasternal short axis view. 
 
The study complies with the Declaration of Helsinki and the Ethics and Human Research 
Committee of The Queen Elizabeth Hospital granted approval for the study. All participants 
provided prior written informed consent. 
 
 
 
Statistical analyses 
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All data are expressed as mean ± SD unless stated otherwise. Interval changes in functional and 
electrophysiological parameters were assessed using paired t- test for normally distributed 
variables, and Wilcoxon matched-pairs signed rank test for non-parametric data. Each patient 
served as his/her control. Interactions between changes in functional status and changes in 
electrical parameters were correlated using Pearson correlation coefficients for normally 
distributed data and Spearman correlation for non-parametric data. Categorical variables were 
analysed with chi-square and Fisher’s exact test. A two-tailed P value <0.05 was considered 
statistically significant. 
All data were analysed with Prism 7 for Mac OS X version 6.0h October 2016 apart from 
backward stepwise multivariate analysis performed on SPSS version 11.8.2, year 2013. 
 
RESULTS 
 
Baseline Characteristics 
Table 1 shows the patients’ baseline demographics. 17 patients (52%) had underlying ischemic 
aetiology of heart failure and all patients were extensively treated medically. The NICM group 
had higher baseline LVEF of 0.33 ± 0.06 versus 0.26 ± 0.04, p =0.001, and significantly lower 
left ventricular volumes, while diabetes and statin therapy were more frequent among the ICM 
patients. The mean baseline intrinsic QRS duration was 158 ± 27.2ms. There were no significant 
differences in baseline electrical parameters in both groups.  No patient had right bundle branch 
block on the ECG, two had intra-ventricular conduction delay, two were paced and the rest had 
LBBB. Of the initial 33 patients, 1 died a month after CRT insertion and 3 did not return for 
follow-up  
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Changes in mechanical and clinical parameters 
At 6 months, there were significant improvements in LVEF from 31±6 to 38 ±10 percent 
(p<0.001), in mechanical dyssynchrony as assessed with IVMD 43.6± 44.6 to 19.9±33.9ms 
(p=0.012) and in symptomatic status as measured with the QOL score 40.7±25.4 to 22.9 
±22.3 (p =0.001) in the whole cohort (Table 2). Notably, although at baseline the NICM 
group had better LV systolic function than the ICM group, at 6 months post CRT insertion, 
there were significant improvements in LVEF and LVESV in both groups and no significant 
differences between groups for LVEF or LVESV changes. 
 
 
Changes in electrical parameters 
In terms of electrical parameters, at 6 months, there was a trend towards reduction in intrinsic 
QRS duration in the whole cohort (159 ± 23.7 to 148 ± 29.4ms, p =0.082) and this was driven by 
significant reduction in iQRSD in NICM patients (165.4 ± 20.3 to 140.5 ± 28.6ms, p =0.012) 
(Table 3). There was no significant change in iQRSD in the ICM cohort from 153 ± 25.6 to 154 ± 
28.4ms, p= 0.81. Consistent with these data, the decrease in iQRSD in NICM patients was 
statistically greater than that in the ICM group (p = 0.017).  
 
A similar pattern of results was found with the electrophysiological parameter of LVp-RVegm. In 
the whole cohort, there was significant reduction in LVp-RVegm from 116.7 ± 44.5 to 97.0 ± 
45.0ms (p=0.019) (Figure 2 A) and this was driven by the NICM group (121 ± 31.4 to 86.4 
±29.0ms, p=0.005) with no significant change in the ICM group (112 ± 56.2 to 109 ± 56.5ms, p= 
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0.76). The between-group difference was also statistically significant (p=0.042). For LVegm-
QRSend calculations, there was significant reduction in the whole cohort from 77.5 ±53.3 to 53.9 
± 35.5ms, p= 0.024 (Figure 2 B) and this was somewhat more marked in the NICM (81.5 ±60.4 
to 48.6 ± 44.3ms,) than in the ICM group (70.6  ± 51.6 to 63.5 ± 30.9ms), none of these 
differences reached statistical significance. 
 
No significant change was observed in RVp-LVegm at 6 months in the whole cohort (86.9± 39.6 
to 93.3ms, p= 0.30) and no significant change in RVegm-LVegm. These data are shown in Table 
3. 
 
A positive correlation was observed between change in iQRSD and change in LVegm-QRSend 
(Figure 2 D) but with no significant change in Q-LVegm at 6 months, (Figure 2 C). Although 
there was no significant improvement in VO2 max at six months, there was a significant negative 
correlation in individual patients between change in VO2 max and LVp-RVegm (r = -0.42, 
p=0.035). There was also significant positive correlation between changes in QOL score and 
those in the iQRSD (r = 0.39, p=0.04 Figure 3 A/B). We have nonetheless found no significant 
correlation between changes in LVp-RVegm and those of QOL score (r=0.24, p=0.20). There 
was also no significant correlation between changes in iQRSD and those of VO2max (r=-
0.06, p=0.76) 
 
Importantly, there was no significant correlation (r=0.18, p=0.37) between extent of electrical 
remodelling as measured by changes in iQRSD and that of mechanical remodelling, as measured 
by changes in IVMD. 
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Univariate correlates of reduction in intrinsic QRS complex duration: 
On univariate analysis, lower baseline LVEDV and lower baseline LVESV were significantly 
associated with subsequent reduction in iQRSD, (r = -0.43, p = 0.037 and r= -0.40, p = 0.049 
respectively). Baseline LVEF however, was not significantly associated with subsequent 
reduction in iQRSD (r = 0.20, p = 0.32). In spite of this finding, neither changes in LVEDV nor 
changes in LVESV or in LVEF were significantly associated with changes or reduction in 
iQRSD. Also, there was no significant association between age or the presence of diabetes with 
subsequent changes in iQRSD (r= 0.03, p= 0.87 and r= 0.03; p= 0.89 respectively). On the other 
hand, female gender and non-ischemic aetiology were significantly associated with subsequent 
reduction in iQRSD, ( r= 0.41, p= 0.031 and r= 0.42, p= 0.028 respectively). These univariate 
correlates are   shown in Table 4. 
 
Multivariate correlates of reduction in intrinsic QRS complex duration: 
Multivariate analysis of changes in iQRSD performed on pre-defined variables of age, diabetes, 
gender, IVMD, aetiology and LVEDV showed that only non-ischemic aetiology was a significant 
correlate of reduction in iQRSD with β= -0.44, P =0.023 (Table 5) 
 
Correlations between reductions in LVp-RVegm and changes in echocardiographic 
volumes and function 
There was no significant correlation between reductions in LVp-RVegm  and LVEDV (r= -.03, P 
= 0.87) nor with LVESV (r= -.07, P = 0.74) or with changes in LVEF ( r= 0.06, P =0.77). 
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DISCUSSION. 
In this study, we were able to demonstrate firstly that our cohort in general had effective cardiac 
resynchronization at 6 months as shown by significant improvements in echocardiographic and 
functional parameters. In addition to these, we also observed overall significant improvements in 
the electrical parameters of iQRSD, LVp-RVegm, and LVegm-QRSend. Importantly, these 
changes tended to be accentuated in the NICM group rather than the ICM group. Although on 
univariate analysis, smaller baseline left ventricular volumes were associated with reduction in 
intrinsic QRS duration, the significance of this finding is not fully clear especially as changes in 
left ventricular volumes  and function were not associated with changes in iQRSD. Similarly, 
changes in left ventricular volumes and function were not associated with changes in LVp-
RVegm. We also found that on univariate analyses, female gender and NICM were significantly 
associated with subsequent reduction in iQRSD. However, on multivariate analysis, the only 
significant correlate of extent of reduction in iQRSD was NICM aetiology of heart failure, even 
when LVEDV was included in the analysis and this is in spite of the significantly greater baseline 
left ventricular volumes in the NICM group, These findings are consistent with the fact that 
patients with NICM generally respond better to CRT than patients with ICM aetiology[16, 17].  
 
There was no significant difference in mechanical remodelling, as measured by changes in IVMD 
between ICM and NICM patients. Furthermore, irrespective of the smaller baseline left 
ventricular volumes in the NICM in our group, both the ICM and the NICM groups achieved 
significant reduction in LVESV at 6 months and with in-between group reductions being 
statistically insignificant, (p= 0.57 for heterogeneity). Therefore improvement in electrical 
parameters in the NICM group are independent of changes in mechanical remodelling and left 
ventricular volumes. There are two potential explanations for the selective reduction in iQRSD 
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and LVp-RVegm in NICM patients: either the absence of extensive myocardial scarring in such 
patients facilitates potential changes in electrical conduction, and/or the absence of extensive 
myocardial scarring is a pre-requisite for CRT-associated improvements in myocardial energetics 
as postulated by Lidner et al [18] who found that CRT induces selective increase in regional 
myocardial oxygen consumption and blood flow in NICM patients but not in ICM which leads to 
facilitated intra-ventricular electrical conduction. Furthermore, there was no significant 
correlation between extent of electrical and of mechanical remodelling. Therefore, functional 
improvement correlates of the extent of electrical remodelling cannot be regarded as surrogates 
reflecting the beneficial effects of amelioration of mechanical dyssynchrony. It is possible that 
this better response in the NICM may partly be due to their having significant improvement in 
electrical remodelling. A sub-analysis of the CARE-HF trial[19] found that QRS duration at 3 
months post CRT implant but not QRS duration at baseline, predicted mortality and hospitalized 
heart failure, again highlighting the benefits associated with improvement in electrical 
remodelling. Similarly, a retrospective analysis of 337 patients by Iler et al,[20] found after 
adjustments for confounders that wider QRS duration after CRT implant but not at baseline 
independently predicted mortality or heart transplantation. Reduction in intrinsic QRS duration in 
our NICM group may be an indicator that the electrical dyssynchrony in this group reflects 
functional rather than anatomic block in the left bundle. Consistent with this notion, Auricchio et 
al [12] have demonstrated that patients with systolic heart failure and left bundle branch block 
could have a functional block that potentially could be ameliorated with pacing or an anatomic 
block that is fixed. Interestingly, two-thirds of their patients with functional block had non-
ischemic aetiology of heart failure.  
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Although, QRS duration and morphology remain the best tools at present to select patients for 
CRT insertion, recent evidence has cast doubt on the reliability of a simple dichotomization. For 
instance, Sassone et al [21] retrospectively evaluated 243 patients and found that in patients with 
left bundle branch block who underwent CRT insertion, the effect of baseline intrinsic QRS 
duration on echocardiographic responsiveness and event free survival followed a U-shaped curve 
with worse outcomes for QRS duration less than 120-130ms or greater than 180ms. Importantly, 
this analysis includes both ICM and NICM patients. A much greater QRS duration may therefore 
reflect more extensive and potentially irreversible conduction blocks that not only affect the His-
Purkinje system but also the myocardium. Hence we evaluated other measures of electrical 
remodelling with the subsequent novel finding of significant reduction in conduction times from 
the left ventricle to the right ventricle with left ventricular-only pacing, which was accentuated in 
the NICM group only. Given that no significant change occurred in conduction times from the 
right ventricle to the left ventricle with right ventricular-only pacing, it is likely that the enhanced 
conduction time with left ventricle-only pacing is due to improvement in left ventricular intra-
myocardial electrical conduction rather than improvement in the His-bundle conduction. This 
would agree with previous findings by Auricchio et al[12] who noted that one-third of their heart 
failure patients with LBBB had intact transseptal conduction times  and near- normal left 
ventricular endocardial activation times. The authors therefore concluded that in these patients, 
the LBBB is mainly due to left ventricular intra-myocardial conduction delay. A rigorous 
evaluation of canine models of left bundle branch block by Strik et al[22] also found that both 
epicardially and endocardially implanted CRTs improve intramural electrical activation in the left 
ventricle, again making it less likely that improvement in His-Purkinje conduction post CRT 
represent the principal basis for improved electrical remodelling. 
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 In our study group, we also found that with pacing briefly turned off at 6 months, CRT 
significantly reduced the difference between intrinsic QRS duration and the time interval from 
the onset of QRS complex to the onset of the left ventricular intra-cardiac electrocardiogram, 
(LVegm-QRSend), which was driven by reduction in intrinsic QRS duration without affecting 
the time interval between the onset of RV intra-cardiac electrocardiogram and the onset of LV 
intra-cardiac electrocardiogram or Q-LVegm. In other words, the time taken to initiate left 
ventricular depolarization remains unaltered, but once initiated, it takes less time to complete 
ventricular contraction. This finding also supports the hypothesis of improvement in left 
ventricular intra-mural conductivity rather than His-bundle conduction or right ventricular 
conduction.  This could also explain why there was no improvement in the RVegm-LVegm 
which measures time interval for spontaneous depolarization of both ventricles. When all these 
measurements of electrical remodelling are considered together, we can conclude that in our 
cohort, CRT did not result in improvement in RV and/or His-bundle conduction but in 
improvement in left ventricular intra-myocardial conduction. Interestingly, Knuuti et al [23] in 
their study of ten patients with NICM found that CRT improved regional left ventricular 
myocardial oxidative but had no effect on the right ventricular myocardial oxidative metabolism 
at rest. 
 
The consistent finding of improvement in electrical parameters in the NICM group in our study 
may contribute to the selective reduction in all-cause mortality of CRT-D over CRT-P only in 
patients with ischemic aetiology of heart failure but not in patients with NICM [24], perhaps 
indicating that CRT-P resulted in improvements in electrical remodelling in the NICM group 
only and thus mitigating the need for high voltage therapy.  
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Interestingly, the improvement in LVp-RVegm in our NICM group was also significantly 
correlated directly with change in VO2 max at 6 months although no overall change occurred in 
VO2 max itself. No study, to the best of our knowledge has shown this relationship, although 
improved ventricular activation has been shown to result in improved haemodynamics[22]. 
Further re-enforcing the postulate that improvement in electrical remodelling could lead to 
improvement in functional status is our finding of a direct correlation between improvement in 
QOL score and reduction in intrinsic QRS duration at 6 months, in spite of the fact that in our 
cohort, change in QOL did not correlate with changes in measures of mechanical dyssynchrony. 
Our findings would therefore suggest that CRT-induced reversal of electrical remodelling could 
potentially lead to improvement in functional status independent of improvement in mechanical 
effects. The mechanisms underlying this observation remain uncertain, but a previous study 
found that reduction in intrinsic QRS duration 12 months post CRT implant was associated with 
improvement in NYHA functional status.[25] 
 
LIMITATIONS 
Our study is limited by the small number of participants with the resultant potential for ‘false 
negative’ results by virtue of Type II error. 
The NICM group also had higher left ventricular systolic functions at baseline, which might 
contribute, to some of the observed findings. However both groups responded well 
echocardiographically and clinically. In addition both groups had similar baseline electrical 
parameters thus suggesting a disconnect between ‘severity’ of mechanical and electrical 
remodelling.. 
 
CONCLUSION 
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CRT reverses electrical remodelling and selectively improves left ventricular intramyocardial 
electrical conduction in patients with non-ischemic aetiology of heart failure. There seems to be a 
substantial disconnect between ‘severity’ of mechanical and electrical changes. Ultimately, 
improvements in electrical remodelling are associated with improvement in functional status 
independent of changes in echocardiographic mechanical dyssynchrony.  
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Figure 1. Changes in intrinsic QRS duration in the non-ischemic (NICM) and the ischemic 
groups 
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Figure 1: Changes in intrinsic QRS duration in the non-
ischemic (NICM) and the ischemic (ICM) groups
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Figure 2. 
Electrical 
changes 6 
months 
post CRT implant 
A: LVp-RVegm, paired t-test: p =0.019 
B: LVegm-QRSend, paired t-test: p = 0.024 
C: Q-LVegm, paired t-test: p = 0.54 
D: Correlation between change in intrinsic QRS duration and change in LVegm-QRSend: r = 
0.52, p = 0.005 
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Figure 3. Correlations between electrical changes and functional status 6 months post CRT 
implant 
A: LVp-RVegm and VO2 max: r= -0.42, p= 0.035 
B: iQRSD and QOL: r=0.39, p= 0.044 
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Table 1: Baseline characteristics of patients 
Normally distributed data are mean ± SD; skewed data are expressed as median values and interquartile values 
 ALL (n=33) ICM (n=17) NICM (n=16) Unpaired t –
test, p-value 
Age (years) 71.2 ±9.7 71.8 ± 10.2 71 (68.3-77.5) 0.64 
Female, n (%) 10 (30.3) 3 (17.6) 7 (43.7) 0.10 
BMI (kg/m2) 29.3 ± 6.1 28 ± 6.45 30.7 ± 5.6 0.21 
Comorbidities: 
 Hypertension, n (%) 
 Diabetes, n (%) 
 Atrial fibrillation, n (%) 
 eGFR (ml/min/1.73m2) 
 
 
21 (64) 
14 (42) 
5 (15) 
56.2 (21.9) 
 
 
12 (70.5) 
10 (58.8) 
2 (11.7) 
53.1 (22.9) 
 
9 (56.2) 
4 (25) 
3 (18.7) 
59.7 (21.0) 
 
0.39 
0.04 
0.57 
0.39 
Medications: 
 ACE inhibitor 
 Angiotensin receptor blocker 
 Beta Blocker 
 Aldosterone Antagonist 
 Digoxin 
 Furosemide 
 Statin 
 Aspirin 
 Amiodarone 
 
 
22 (67) 
8 (24) 
25 (76) 
18 (55) 
9 (27) 
24 (73) 
18 (55) 
17 (52) 
2 (6.0) 
 
11 (64.7) 
5 (29.4) 
13 (76.4) 
8 (47.0) 
4 (23.5) 
13 (76.4) 
13 (76.4) 
10 (58.8) 
2 (11.7) 
 
11 (68.7) 
3 (18.7) 
12 (75.0) 
10 (62.5) 
5 (31.2) 
11 (68.7) 
5 (31.2) 
7 (43.7) 
0 (0.0) 
 
 
>0.99 
0.68 
>0.99 
0.49 
0.61 
0.70 
0.01 
0.49 
0.48 
CLINICAL ASSESSMENT 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Heart rate (bpm) 
VO2max (ml/min/kg) 
QOL Score 
 
126± 17.1 
71.2 ± 9.2 
69 ± 13.6 
13.8 ± 4.7 
41.9 ± 25.6 
 
125 ± 18.6 
69.3 ± 9.0 
70.4 ± 11.6 
12.0 ± 4.0 
45.6 ± 26.0 
 
130 ± 16.8 
73.8 ± 8.9 
67.5 ± 15.7 
15 ± 4.7 
38 ± 25.5 
 
0.44 
0.16 
0.54 
0.07 
0.40 
VENTRICULAR FUNCTION 
LVESV (ml) 
LVEDV (ml) 
EF (%) 
IVMD (ms) 
 
137±55.3 
193±67.4 
29.8±6.1 
43.9 ± 44.0 
 
166 ± 53.0 
224 ± 64.5 
26 ± 4.0 
34.1 ± 45.7 
 
108 ± 42.8 
161 ± 55.9 
33 ± 6.0 
53.0 ± 41.7 
 
0.002 
0.006 
0.001 
0.24 
ELECTRICAL PARAMETERS 
iQRSD (ms) 
LVp-RVegm (ms) 
RVp-LVegm (ms) 
LVegm-QRSend (ms) 
RVegm-LVegm (ms) 
Q-LVegm (ms) 
 
 
158 ± 27.2 
118 ± 43.3 
88.5 ± 38.6 
72.0 ± 53.1 
57.9 ± 35.1 
88.6 ± 45.7 
 
 
156 ± 24.9 
115 ± 52.4 
96.8 ± 39.5 
67.1 ± 47.4 
62.2 ± 39.5 
89.2 ± 48.9 
 
 
161 ± 29.6 
121 ±31.4 
79.2 ± 36.7 
64.6 ± 53.3 
52.9 ± 29.8 
87.9 ± 43.3 
 
 
0.62 
0.69 
0.20 
0.89 
0.47 
0.94 
 
BMI: Body mass index; VO2max: peak oxygen consumption during exercise; QOL: Quality of life score 
using Minnesota Living with Heart Failure questionnaire; iQRSD: Intrinsic QRS duration; LVp-RVegm: 
onset of left ventricular pacing to onset of right ventricular intracardiac electrocardiogram; RVegm-
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LVegm: onset of right ventricular intracardiac electrocardiogram to onset of left ventricular intracardiac 
electrocardiogram; RVp-LVegm: onset of right ventricular pacing to the onset of left ventricular 
intracardiac electrocardiogram;  LVP-QRSend: onset of left ventricular pacing to the end of QRS complex. 
Q-LVegm: the interval between the onset of QRS and the onset of   left ventricular intra-cardiac 
electrocardiogram; IVMD: inter-ventricular mechanical delay 
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Table 2: Effects of cardiac resynchronization therapy on clinical and echocardiographic parameters 
in the whole cohort.  
Normally distributed data are mean ± SD; skewed data are expressed as median values and interquartile values 
 
Parameters ALL   NICM   ICM    
 Pre-CRT Post-CRT P-value Pre-CRT Post-CRT P-value Pre-CRT Post-CRT P-value P for 
heterogeneity 
CLINICAL 
VO2max (ml/min/kg) 
QOL score 
 
13.8 (4.67) 
40.7 (25.4) 
 
14.1 (5.3) 
22.9 (22.3) 
 
0.80 
0.001 
 
15.4 (4.8) 
35.2 (23.8) 
 
15.9 (5.4) 
15.4 (12.3) 
 
0.63 
0.003 
 
12.0 (3.9) 
46.5 (26.7) 
 
11.8 (4.3) 
31.0 (27.9) 
 
0.85 
0.20 
 
 
0.66 
ECHOCARDIOGRAPHIC 
LV EF (%) 
LVEDV (ml) 
LVESV (ml) 
IVMD (ms) 
 
31.0 (6.0) 
193 (69.8) 
137 (57.5) 
43.6 (44.6) 
 
38.0 (10.0) 
152 (66.7) 
98.9 (52.1) 
19.9 (33.9) 
 
<0.001 
<0.001 
<0.001 
0.012 
 
34.5 (5.8) 
145 (121.7-318.7) 
106 (45.9) 
54.6 (42.6) 
 
42.2 (10.2) 
109 (37.6) 
64.2 (31.5) 
29.0 (25.0) 
 
0.006 
<0.001 
<0.001 
0.08 
 
26.9 (3.3) 
227 (64.8) 
167.2 (52.4) 
30.8 (45.0) 
 
 
34.0 (9.0) 
197 (60.8) 
133 (45.5) 
9.54 (40.9) 
 
 
0.013 
0.11 
0.046 
0.07 
 
0.87 
0.88 
0.57 
 
 
               VO2max: peak oxygen consumption during exercise; QOL: Minnesota Living with Heart Failure questionnaire; LVEF: left ventricular ejection fraction; 
               LVED: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume; IVMD: interventricular mechanical delay; NICM: non-ischemic 
cardiomyopathy; ICM: ischemic cardiomyopathy
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Table 3: Electrical changes following cardiac resynchronization therapy. 
 
Data are normally distributed and are expressed as mean ± SD.  
 
iQRSD: Intrinsic QRS duration; LVp-RVegm: onset of left ventricular pacing to onset of right ventricular intracardiac electrogram; RVegm-LVegm: onset of 
right ventricular intracardiac electrocardiogram to onset of left ventricular intracardiac electrocardiogram; RVp-LVegm: onset of right ventricular pacing to 
the onset of left ventricular intracardiac electrocardiogram;  LVP-QRSend: onset of left ventricular pacing to the end of QRS complex; NICM: non-ischemic  
cardiomyopathy; ICM: ischemic cardiomyopathy. 
   
 ALL NICM ICM  
Parameters Baseline 6months p-
value 
Baseline 6months p-
value 
Baseline 6months p-
value 
P for 
heterogeneity 
           
iQRSD (ms) 159 (23.6) 148 (29.4) 0.082 165 (20.3) 140 (28.6) 0.012 153 (25.6) 154 (28.4) 0.81 0.017 
LVp-RVegm (ms) 117 (44.5) 97.0 (45.0) 0.019 121(31.4) 86.4 (29.0) 0.005 112 (56.2) 109 (56.5) 0.76 0.042 
LVEgm-QRSend (ms) 77.5 (53.3) 53.9 (35.5) 0.024 81.5 (60.4) 48.6 (44.3) 0.064 70.6 (51.6) 63.5 (30.9) 0.55 0.21 
Q-LVegm (ms) 86.1 (47.1) 91. 4 (43.4) 0.54 90.4 (43.9) 92.3 (46.5) 0.9 82.0 (51.2) 90.6 (42.2) 0.4  
Rvegm-Lvegm (ms) 55.1 (34.4) 57.8 (33.6) 0.48 55.2 (29.5) 52.5 (25.1) 0.87 55.0 (39.5) 63.1 (40.7) 0.25  
RVp-LVegm(ms) 86.9 (39.6) 93.3 (37.9) 0.30 79.2(36.6) 78.6(32.9) 0.93 95.1(42.3) 109 (37.4) 0.17  
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Table 4: Univariate determinants of reduction in iQRSD at 6 months post CRT insertion 
 
 
 
 
 
 
 
 
 
 
 
LVEDV: left ventricular end-diastolic volume; LVESV: left ventricular end-systolic volume;  
LVEF: left ventricular ejection fraction, IVMD: Inter-ventricular mechanical delay 
 
 
 
 
 
 
 
Variable r-value p-value 
Baseline LVEDV (ml)  -0.43 0.037 
Baseline LVESV (ml)  -0.40 0.049 
Baseline LVEF (%)   0.20 0.32 
Baseline IVMD (ms)  -0.02 0.89 
Change in LVEDV (ml)   0.21 0.31 
Change in LVESV (ml)   0.18 0.39 
Change in LVEF (%)   0.14 0.51 
Age   0.03 0.87 
Aetiology   0.42 0.028 
Diabetes   0.03 0.89 
Gender   0.41 0.031 
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Table 5: Multivariate determinants of reduction in iQRSD at 6 months following CRT 
Parameter Standardized coefficients beta P-Value 
Diabetes  0.23 0.24 
Gender 0.27 0.18 
Age  -0.30 0.76 
IVMD (ms) -0.03 0.85 
Aetiology -0.44 0.023 
LVEDV (ml) -0.18 0.38 
 
IVMD: interventricular mechanical delay; LVEDV: left ventricular end-diastolic volume. 
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Highlights  
 
 CRT reduced iQRSD in patients with non-ischemic cardiomyopathy. 
 CRT decreased intramyocardial conduction times from left to right ventricles. 
 Improvement in electrical remodelling correlated with functional improvement. 
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